

Primary Gastric Melanoma: A Rare Cause of Upper Gastrointestinal Bleeding

Anupama Ravi, MD

*Division of Digestive Diseases, Emory University,
Atlanta, Georgia*

Primarily gastrointestinal malignant melanoma is an unusual clinical entity. Rarer still is primary gastric melanoma. Most melanomas found in the stomach are metastases from cutaneous sources.¹ Primary gastric melanoma is underdiagnosed, its symptoms and signs are nonspecific, and specific staining techniques must be used to confirm the diagnosis. The following case of primary gastric melanoma involves a middle-aged white man who initially presented with upper gastrointestinal bleeding.

Case Report

A 50-year-old white man presented after 3 episodes of hematemesis and 1 episode of melena. He had a 9-month history of worsening epigastric pain and a 20-pound weight loss over the previous month, and his past medical history was significant for hypertension, pancreatitis, and peptic ulcer disease. In addition, the patient was a 40-pack-per-year smoker and a former alcoholic, and his family history was deemed noncontributory. On examination, the patient was hypotensive but not tachycardic, and pallor of the conjunctiva and mild epigastric tenderness were seen. Laboratory results were significant for a hemoglobin of 7.5 g/dL and hematocrit of 23.1%. Upper endoscopy revealed a large necrotic ulcerated mass extending from the antrum to the body of the stomach (Figure 1). Computed tomography scan of the abdomen was remarkable for thickening of the posterior wall of the body of the stomach, with the mass extending into the gastric lumen and the adjacent fat with 2 enlarged lymph nodes (Figure 2). Surgery demonstrated a mass measuring 12 cm × 10.5 cm × 2.5 cm involving 50% of the stomach, including the gastrocolic ligaments, and extending into

the pancreas. Palliative resection was performed. Histopathology showed neoplastic cells in a sheet-like growth pattern showing no glandular differentiation (Figure 3). S100 protein, HMB-45 antibodies, and Melan A staining were strongly positive, thus confirming a diagnosis of gastric melanoma (Figure 4). The patient denied any history of cancerous lesions of the skin. A complete examination of his skin, including oral and anal mucosa, showed no suspicious lesions, and fundoscopic examination of the eye was normal. A diagnosis of advanced primary gastric melanoma was made. The patient was discharged to a correctional facility and subsequently lost to follow-up.

Discussion

Malignant melanoma most commonly develops in the skin. The vast majority of gastrointestinal melanomas are metastases from a cutaneous primary tumor.¹ In rare instances, primary malignant melanoma can arise from mucosa of the gastrointestinal tract, particularly from the



Figure 1. Upper endoscopy revealed a large necrotic ulcerated mass extending from the antrum to the body of the stomach.

Address all correspondence to:

Dr. Anupama Ravi, Emory University, Division of Digestive Diseases,
615 Michael Street, Whitehead Research Building, Atlanta, GA 30322;
Tel: 404-918-4303; E-mail: anupravi@gmail.com




Figure 2. Contrast-enhanced computed tomography scan of the abdomen demonstrated thickening of the posterior wall of the body of the stomach with extension of the mass into the gastric lumen and into the adjacent fat (yellow arrow) with 2 enlarged lymph nodes.

esophagus, anorectum, and small bowel.² Fewer than 15 cases of primary gastric melanoma have been documented in the literature.³⁻⁶

There has been speculation in the past as to whether primary melanoma can occur in the stomach, as benign melanocytes are absent in the normal gastric wall. However, melanosis of the stomach has been well documented in the case of anal and esophageal melanoma.^{6,7} Thus, it is possible that primary gastric melanoma can occur in unusual circumstances.

Criteria for the diagnosis of primary gastric melanoma include the absence of concurrent lesions and the lack of a history of melanoma or atypical melanocytic lesion removal from the skin or other organs.⁸ Disease-free survival of at least 12 months after curative surgical excision of the involved organ has been proposed as a criterion for the distinction of a primary lesion from a metastatic lesion, as 50% of patients with stage IV melanoma of the skin or visceral disease from an unknown primary lesion die 12 months after diagnosis.⁹

The clinical manifestations of primary gastric melanoma are similar to those of other gastric tumors, with weight loss, upper gastrointestinal bleeding, and anemia as the most common symptoms. Most patients are asymptomatic until the tumor becomes advanced. Computed tomography scan of the abdomen, upper endoscopy, and subsequent biopsy are the main diagnostic modalities. On upper endoscopy, a mass-like lesion with black pigmentation may be seen. Immunohistochemical stains with




Figure 3. Biopsy of the mass showed neoplastic cells in a sheet-like growth pattern showing no glandular differentiation (hematoxylin & eosin stain, $\times 200$).




Figure 4. Tumor cells were strongly positive for immunoperoxidase staining for Melan A ($\times 200$).

S100 protein, Melan-A, and HMB-45 antibodies have increased the diagnostic sensitivity of biopsy and cytology and play a key role in the diagnosis of these lesions.¹⁰ Chemotherapy options include interferon, interleukin-12, and other agents.^{8,11} Prognosis is extremely poor due to the frequent delay in diagnosis, the inherently more aggressive nature of the tumor, and earlier dissemination due to the rich lymphatic and vascular supply of the gastrointestinal mucosa.¹²

Primary gastric melanoma is an extremely uncommon clinical entity. Amelanotic melanoma such as the one in this case can be missed in poorly differentiated tumors unless appropriate staining tests are performed. Primary malignant melanoma of the stomach may be an underdiagnosed phenomenon. Early detection and surgical intervention is critical for long-term cure,⁴ though overall prognosis is very poor.

I would like to acknowledge Dr. Robert Osburne for providing guidance with the manuscript.

References

1. Washington K, McDonagh D. Secondary tumors of the gastrointestinal tract: surgical pathologic findings and comparison with autopsy survey. *Mod Pathol.* 1995;8:427-433.
2. Aagaard MT, Kristensen IB, Lund O, Hasenkam JM, Kimose HH. Primary malignant non-epithelial tumours of the thoracic oesophagus and cardia in a 25-year surgical material. *Scand J Gastroenterol.* 1990;25:876-882.
3. Chandler AB, Jones GF. Malignant melanoma of the gastrointestinal tract: a case report. *Am J Surg.* 1951;17:719-721.
4. Alazmi WM, Nehme OS, Regalado JJ, Rogers AI. Primary gastric melanoma presenting as a nonhealing ulcer. *Gastrointest Endosc.* 2003;57:431-433.
5. Lagoudianakis EE, Genetzakis M, Tsekouras DK, Papadima A, Kafri G, et al. Primary gastric melanoma: a case report. *World J Gastroenterol.* 2006;12:4425-4427.
6. Alberti JE, Bodor J, Torres AD, Pini N. Primary malignant melanoma of the esophagus associated with melanosis of the esophagus and stomach [in Spanish]. *Acta Gastroenterol Latinoam.* 1984;14:139-148.
7. Horowitz M, Nobrega MM. Primary anal melanoma associated with melanosis of the upper gastrointestinal tract. *Endoscopy.* 1998;30:662-665.
8. Elsayed AM, Albahra M, Nzeako UC, Sobin LH. Malignant melanomas in the small intestine: a study of 103 patients. *Am J Gastroenterol.* 1996;91:1001-1006.
9. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer.* 1998;83:1664-1678.
10. Blecker D, Abraham S, Furth EE, Kochman ML. Melanoma in the gastrointestinal tract. *Am J Gastroenterol.* 1999;94:3427-3433.
11. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. *Clin Cancer Res.* 1997;3:409-417.
12. Sachs DL, Lowe L, Chang AE, Carson E, Johnson TM. Do primary small intestinal melanomas exist? Report of a case. *J Am Acad Dermatol.* 1999;41:1042-1044.

Review

Waleed M. Alazmi, MD

*Department of Medicine, Faculty of Medicine,
Kuwait University*

The dearth of information regarding mucosal melanoma corresponds with the rarity of the disease. In a review of 84,836 melanoma cases from the National Cancer Data Base that were entered between 1985 and 1994, 91.2% were cutaneous, 5.2% were ocular, 1.3% were mucosal, and 2.2% were unknown primaries.¹ Mucosal melanoma was first described by Weber in 1856 and later classified as a distinct entity in 1869.^{2,3} In the United States, the incidence of cutaneous melanoma continues to rise at a rate higher than that of any other form of cancer. The incidence of noncutaneous melanoma, however, remains stable. Exposure to ultraviolet radiation is a major predisposing factor to cutaneous melanoma. The occurrence of melanoma in areas of the body that have never been exposed to sunlight, such as the gastrointestinal tract, may provide important insights into the pathogenesis of melanoma in general.

Ravi reported a case of upper gastrointestinal bleeding due to a primary gastric melanoma⁴ and noted that the tumor is extremely rare and has a very poor prog-

nosis. A high index of clinical suspicion is essential to reach this diagnosis. Unusual appearance or nonhealing gastric ulcers should prompt the endoscopist to obtain multiple biopsies and consult with the pathologist to reach a diagnosis.

The distribution of mucosal melanomas tends to center near mucocutaneous junctions, where the melanomas are thought to arise from melanocytes that have migrated from the neuroectoderm and undergone malignant transformation. Their function in these locations is believed to differ from that of cutaneous melanocytes and likely has been the reason for the lack of understanding of this malignancy. Malignant melanoma can arise in gastrointestinal mucosal sites such as the esophagus,⁵ anorectum,⁶ and small bowel.^{7,8} Cases of primary melanoma of the stomach have rarely been reported.⁹⁻¹¹ The debate over the nature of such lesions early in development still persists. Thus, specific criteria have been proposed for the diagnosis of primary melanoma, including the absence of concurrent lesions and the lack of a history of melanoma or atypical melanocytic lesion removal from the skin or other organs.⁶ Partial or complete regression of melanocytic nevi and melanomas is well recognized.¹² However, there are no data as to how many melanomas regress completely without metastasis. The exact mechanism of regression remains unknown and is difficult to study.¹³ Such knowledge would provide an insight into cancer immunology, in general, and melanomas, in particular.

It is known that melanocytes come from neural crest cells and migrate to the skin, hair follicles, and retina; however, their function in the mucosa is not certain. Melanin may be seen in the submucosa of the

Address correspondence to:

Dr. Waleed Alazmi, Department of Medicine, Faculty of Medicine, Kuwait University, P. O. Box 24923, Safat 13110, Kuwait; E-mail: waleed@hsc.edu.kw

oral cavity due to phagocytosis by macrophages. Whether from injury, hormone response, or congenital factors, a variety of melanocytic lesions present clinically as both benign and malignant.¹⁴ Diagnostic studies have been performed to further identify mucosal melanomas as a separate entity from cutaneous melanomas by using a panel of antibodies and looking for various markers seen in the cutaneous form.¹⁵ Most of these studies have been performed retrospectively and have been analyzed immunohistochemically for melanoma-associated antigens. Stains for S100, HMB-45, and antivimentin were strongly associated with mucosal melanomas, but they were not pathognomonic for the disease due to other neural crest-derived tumors known to be associated with these substances.¹⁶ The applicability of these studies can aid in differentiating melanomas from other poorly differentiated tumors. Unfortunately, the laborious process of performing these studies and the similar expression patterns found in cutaneous melanomas can prove to be challenging when differentiating a primary mucosal melanoma from a metastatic one.

Metastatic melanoma in the gastrointestinal tract is relatively uncommon; an antemortem diagnosis is made in 1–4% of patients with malignant melanoma. The small bowel is the most commonly involved site in metastasis occurring in the gastrointestinal tract.¹⁷ Despite nonspecific gastrointestinal symptoms, metastatic melanoma should be suspected in patients with a history of melanoma and acute gastrointestinal symptoms. Although long-term survival remains poor, complete surgical resection of macroscopic viable tumors affords prolonged survival compared with that of palliative resection or medical treatment.

Recommendations regarding appropriate treatment strategies have been proposed in the recent literature.¹⁸ Initially, radical surgery was advocated as the mainstay of therapy; however, local recurrence and survival rates were unchanged regardless of whether radical surgery or local excision was performed, and the most recent data have favored the conservative approach when appropriate. Unfortunately, a multitude of adjuvant therapies have been tried without any success. Adjuvant radiotherapy plays a role when combined with surgery, but this option is reserved for nodal and locoregionally advanced disease and has had no effect when used as a prophylactic method. Potential therapies based upon new biologic and immunologic findings may have promise in the future to impact this disease. Until then, this aggressive disease continues to have a poor prognosis, and surgical resection continues to be the mainstay of primary therapy.¹⁹

In summary, primary mucosal melanoma, particularly gastric melanoma, represents an extremely rare malignancy that does not have the same risk factors or behavior patterns as cutaneous melanoma. This malignancy occurs in areas that are not exposed to the sun, and its solid predisposing risk factors have not been identified, making the disease very difficult to diagnose or screen for. Primary mucosal melanoma is usually diagnosed at a later stage and carries a poor prognosis.²⁰ Differentiating a primary lesion from a metastatic melanoma is often challenging, due to the lack of definitive criteria, both pathologically and clinically. The rich vascular and lymphatic networks surrounding these lesions are likely responsible for their aggressive behavior and poor prognosis. In addition, the obscure locations where mucosal melanomas occur are an obvious reason for their late presentation at an advanced stage and hence their often incurable nature.

nancy that does not have the same risk factors or behavior patterns as cutaneous melanoma. This malignancy occurs in areas that are not exposed to the sun, and its solid predisposing risk factors have not been identified, making the disease very difficult to diagnose or screen for. Primary mucosal melanoma is usually diagnosed at a later stage and carries a poor prognosis.²⁰ Differentiating a primary lesion from a metastatic melanoma is often challenging, due to the lack of definitive criteria, both pathologically and clinically. The rich vascular and lymphatic networks surrounding these lesions are likely responsible for their aggressive behavior and poor prognosis. In addition, the obscure locations where mucosal melanomas occur are an obvious reason for their late presentation at an advanced stage and hence their often incurable nature.

References

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer*. 1998;83:1664-1678.
2. Weber CO. Chirurgische Erfahrungen und Untersuchungen, nebst sehrreichen Beobachtungen aus der chirurgischen Klinik und dem evangelischen Krankenhaus zu Bonn. Berlin: G Reimer; 1859.
3. Lucke A. Die Lehre von den Geschwulsten in anatomischer und klinischer Beziehung in Handbuch d. allg. u. spec. chir. *Erlangen*. 1869;244.
4. Ravi A. Primary gastric melanoma: a rare cause of upper gastrointestinal bleeding. *Gastroenterol Hepatol*. 2008;4:795-797.
5. Chalkiadakis G, Wihlm JM, Morand G, Weill-Bousson M, Witz JP. Primary malignant melanoma of the esophagus. *Ann Thorac Surg*. 1985;39:472-475.
6. Christova S, Meinhard K, Mihailov I, Alexiev B. Three cases of primary malignant melanoma of the alimentary tract. *Gen Diagn Pathol*. 1996;142:63-67.
7. Kadivar TF, Vanek VW, Krishnan EU. Primary malignant melanoma of the small bowel: a case study. *Am Surg*. 1992;58:418-422.
8. Sachs DL, Lowe L, Chang AE, Carson E, Johnson TM. Do primary small intestinal melanomas exist? Report of a case. *J Am Acad Dermatol*. 1999;41:1042-1044.
9. Chandler AB, Jones GF. Malignant melanoma of gastrointestinal tract: a case report. *Am Surg*. 1951;17:719-721.
10. Rao GM, Satyanarayana Y, Janaki M, Hayath MS. Primary melanocarcinoma of stomach [abstract]. *Indian J Gastroenterol*. 1999;18:176.
11. Alazmi WM, Nehme OS, Regalado JJ, Rogers AI. Primary gastric melanoma presenting as a nonhealing ulcer. *Gastrointest Endosc*. 2003;57:431-433.
12. Ducic Y. Spontaneous regression of cutaneous melanoma with subsequent metastasis. *J Oral Maxillofac Surg*. 2002;60:588-591.
13. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. *J Natl Cancer Inst*. 2001;93:1047-1048.
14. Trodahl JN, Sprague WG. Benign and malignant melanocytic lesions of oral mucosa. An analysis of 135 cases. *Cancer*. 1970;25:812-823.
15. van Duinen SG, Ruiters DJ, Hageman P, Venneboer C, Dickersin GR, et al. Immunohistochemical and histochemical tools in the diagnosis of amelanotic melanoma. *Cancer*. 1984;53:1566-1573.
16. Kageshita T, Kimura T, Yoshi A, Hirai S, Ono T, Ferrone S. Antigenic profile of mucosal melanoma lesions. *Int J Cancer*. 1994;56:370-374.
17. Blecker D, Abraham S, Furth EE, Kochman ML. Melanoma in the gastrointestinal tract. *Am J Gastroenterol*. 1999;94:3427-3433.
18. Wong JH, Cagle LA, Storm FK, Morton DL. Natural history of surgically treated mucosal melanoma. *Am J Surg*. 1987;154:54-57.
19. Tomicic J, Wanebo HJ. Mucosal melanomas. *Surg Clin North Am*. 2003;83:237-252.
20. McKinnon JG, Kokal WA, Neifeld JP, Kay S. Natural history and treatment of mucosal melanoma. *J Surg Oncol*. 1989;41:222-225.